

Company Number: 605358

**Kells Pharmaceutical Healthcare Services Limited**  
**Abridged Unaudited Financial Statements**  
**for the financial period ended 31 December 2025**

**Kells Pharmaceutical Healthcare Services Limited**  
**CONTENTS**

	<b>Page</b>
Directors and Other Information	3
Directors' Responsibilities Statement	4
Balance Sheet	5
Statement of Changes in Equity	6
Notes to the Financial Statements	7 - 10

**Kells Pharmaceutical Healthcare Services Limited**  
**DIRECTORS AND OTHER INFORMATION**

<b>Directors</b>	Roger Conan Derek Keogh Alexandre Montavon
<b>Company Secretary</b>	Roger Conan
<b>Company Number</b>	605358
<b>Registered Office</b>	12 Camden Row, Dublin 8
<b>Business Address</b>	12 Camden Row, Dublin 8, Dublin
<b>Accountants</b>	Accountable Chartered Certified Accountants 106 12 Camden Row Dublin 8 D08 R9CN Ireland
<b>Bankers</b>	Bank of Ireland Ranelagh Dublin 6

## **Kells Pharmaceutical Healthcare Services Limited DIRECTORS' RESPONSIBILITIES STATEMENT**

for the financial period ended 31 December 2025

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial period. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial period end date and of the profit or loss of the company for the financial period and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

**Signed on behalf of the board**



**Roger Conan**  
Director

**8 April 2026**



**Derek Keogh**  
Director

**8 April 2026**

**Kells Pharmaceutical Healthcare Services Limited**  
**BALANCE SHEET**

as at 31 December 2025

	Notes	Dec 25 €	Jun 25 €
<b>Fixed Assets</b>			
Tangible assets	7	1,287	579
<b>Current Assets</b>			
Debtors	8	10,352	33,963
Cash and cash equivalents		387,616	108,337
		<u>397,968</u>	<u>142,300</u>
<b>Creditors: amounts falling due within one year</b>	9	(32,654)	(4,890)
<b>Net Current Assets</b>		<u>365,314</u>	<u>137,410</u>
<b>Total Assets less Current Liabilities</b>		<u>366,601</u>	<u>137,989</u>
<b>Capital and Reserves</b>			
Called up share capital presented as equity		100	100
Retained earnings		366,501	137,889
<b>Equity attributable to owners of the company</b>		<u>366,601</u>	<u>137,989</u>

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of Kells Pharmaceutical Healthcare Services Limited, state that -

- (a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,
- (b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,
- (c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),
- (d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial period and of its profit or loss for such a financial period and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,
- (e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 8 April 2026 and signed on its behalf by:

  
 Roger Conan  
 Director

  
 Derek Keogh  
 Director

**Kells Pharmaceutical Healthcare Services Limited**  
**STATEMENT OF CHANGES IN EQUITY**

as at 31 December 2025

	<b>Called up share capital €</b>	<b>Retained earnings €</b>	<b>Total €</b>
<b>At 1 July 2024</b>	100	626,265	626,365
Profit for the financial year	-	403,582	403,582
Payment of dividends	-	(891,958)	(891,958)
<b>At 30 June 2025</b>	100	137,889	137,989
Profit for the financial period	-	228,612	228,612
<b>At 31 December 2025</b>	<b>100</b>	<b>366,501</b>	<b>366,601</b>

# **Kells Pharmaceutical Healthcare Services Limited**

## **NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**

for the financial period ended 31 December 2025

### **1. General Information**

Kells Pharmaceutical Healthcare Services Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 605358. The registered office of the company is 12 Camden Row,, Dublin 8. The principal activity of the company consists of pharmaceutical and healthcare market consultancy. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

### **2. Summary of Significant Accounting Policies**

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

#### **Statement of compliance**

The financial statements of the company for the financial period ended 31 December 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

#### **Basis of preparation**

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial period, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

#### **Turnover**

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

#### **Tangible assets and depreciation**

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	- 12.5% Straight line
----------------------------------	-----------------------

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

#### **Trade and other debtors**

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

#### **Trade and other creditors**

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

#### **Employee benefits**

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.

continued

## Kells Pharmaceutical Healthcare Services Limited NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial period ended 31 December 2025

### Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial period and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

### Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.

### Ordinary share capital

The ordinary share capital of the company is presented as equity.

### 3. Period of financial statements

The financial statements are for the 6 month period ended 31 December 2025.

The company changed its financial year-end from 30 June to 31 December. Consequently, the current reporting period covers a six-month period, while the comparative prior period reflects a full twelve-month period.

	Dec 25	Jun 25
	€	€
<b>4. Operating profit</b>		
<b>Operating profit is stated after charging:</b>		
Depreciation of tangible assets	<u>225</u>	<u>342</u>

### 5. Employees

The average monthly number of employees, including directors, during the financial period was 2, (Jun 25 - 2).

	Dec 25	Jun 25
	Number	Number
Directors	<u>2</u>	<u>2</u>

	Dec 25	Jun 25
	€	€
<b>6. Dividends</b>		
Dividends on equity shares:		
Ordinary Shares Class 1 - Final paid	<u>-</u>	<u>891,958</u>

continued

**Kells Pharmaceutical Healthcare Services Limited**  
**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**

for the financial period ended 31 December 2025

<b>7. Tangible assets</b>		
	<b>Fixtures, fittings and equipment</b>	<b>Total</b>
	<b>€</b>	<b>€</b>
<b>Cost</b>		
At 1 July 2025	2,733	2,733
Additions	933	933
	<hr/>	<hr/>
At 31 December 2025	3,666	3,666
	<hr/>	<hr/>
<b>Depreciation</b>		
At 1 July 2025	2,154	2,154
Charge for the financial period	225	225
	<hr/>	<hr/>
At 31 December 2025	2,379	2,379
	<hr/>	<hr/>
<b>Net book value</b>		
At 31 December 2025	<b>1,287</b>	<b>1,287</b>
	<hr/> <hr/>	<hr/> <hr/>
At 30 June 2025	579	579
	<hr/> <hr/>	<hr/> <hr/>
<b>8. Debtors</b>	<b>Dec 25</b>	<b>Jun 25</b>
	<b>€</b>	<b>€</b>
Trade debtors	8,948	25,034
Taxation	1,404	8,929
	<hr/>	<hr/>
	<b>10,352</b>	<b>33,963</b>
	<hr/> <hr/>	<hr/> <hr/>
<b>9. Creditors</b>	<b>Dec 25</b>	<b>Jun 25</b>
<b>Amounts falling due within one year</b>	<b>€</b>	<b>€</b>
Taxation	32,654	1,610
Directors' current accounts (Note 12)	-	260
Accruals	-	3,020
	<hr/>	<hr/>
	<b>32,654</b>	<b>4,890</b>
	<hr/> <hr/>	<hr/> <hr/>
<b>10. Income Statement</b>		
	<b>Dec 25</b>	<b>Jun 25</b>
	<b>€</b>	<b>€</b>
At 1 July 2025	137,889	626,265
Profit for the financial period	228,612	403,582
Payment of dividends	-	(891,958)
	<hr/>	<hr/>
At 31 December 2025	<b>366,501</b>	<b>137,889</b>
	<hr/> <hr/>	<hr/> <hr/>
<b>11. Capital commitments</b>		
The company had no material capital commitments at the financial period-ended 31 December 2025.		
<b>12. Directors' remuneration and transactions</b>	<b>Dec 25</b>	<b>Jun 25</b>
	<b>€</b>	<b>€</b>
Remuneration	28,000	68,041
	<hr/> <hr/>	<hr/> <hr/>

continued

**Kells Pharmaceutical Healthcare Services Limited**  
**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**  
for the financial period ended 31 December 2025

The following amounts are repayable to the directors:

	Dec 25	Jun 25
	€	€
Derek Keogh	-	260
	<u>          </u>	<u>          </u>

**13. Post-Balance Sheet Events**

There have been no significant events affecting the company since the financial period-end.

**14. Approval of financial statements**

The financial statements were approved and authorised for issue by the board of directors on 8 April 2026.